ClinConnect ClinConnect Logo
Search / Trial NCT00459537

Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis

Launched by NOVARTIS · Apr 11, 2007

Trial Information

Current as of May 16, 2025

Completed

Keywords

Toenail Fungus Onychomycosis Nail Fungus Toenail Fungal Infection Tinea Unguium Dermatophytes Foot Dermatoses

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male and females 12 - 75 years of age
  • Fungal toenail infection of one or both of the large (great) toenails
  • The nail infection must be due to a dermatophyte, (mixed infections \[dermatophyte and non-dermatophyte\] are not allowed)
  • The target toenail area must have at least 25% to no more than 75% disease involvement without spikes.
  • Exclusion Criteria:
  • Target foot must not have severe plantar (moccasin) tinea pedis that would require systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be treated with terbinafine prior to baseline or at any time during the trial. Other topical treatments for athlete's foot may be recommended at the discretion of the investigator.
  • Subjects must not have abnormalities of the nail that could prevent a normal appearing nail if clearing of infection is achieved
  • No administration of systemic antifungal medications within 6 months prior to screening visit
  • No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
  • Patients with the target toenail involving the matrix (lunula) or having less than 2mm clear (unaffected) nail plate length beyond the proximal fold.
  • Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail.
  • No professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
  • Known pregnancy or lactation at time of enrollment
  • Other protocol-defined inclusion/exclusion criteria may apply

About Novartis

Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.

Locations

Various Cities, , France

Various Cities, , Germany

Various Cities, , Iceland

Various Cities, , Finland

Various Cities, , Hungary

Various Cities, , Norway

Various Cities, , Poland

Various Cities, , Russian Federation

Various Cities, , Spain

Various Cities, , Turkey

Patients applied

0 patients applied

Trial Officials

Novartis

Study Director

Novartis

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials